Antibody-Drug Conjugate Using Peptide Linker Kills Cancer Cells in Mouse Model
A mouse-canine chimeric ADC using peptide linker technology (CCAP) killed podoplanin-expressing cancer cells in vitro and showed superior anti-tumor activity in vivo.
Quick Facts
What This Study Found
The antibody-drug conjugate P38B-DM1 was constructed using a mouse-canine chimeric antibody (P38B) that targets dog podoplanin, a peptide linker, and the cytotoxic payload emtansine (DM1). Construction used the chemical conjugation by affinity peptide (CCAP) method.
In cell culture, P38B-DM1 killed podoplanin-overexpressing cells in a dose-dependent manner. In a mouse xenograft model, P38B-DM1 showed significantly higher anti-tumor activity than the antibody alone (P38B).
The peptide linker and CCAP conjugation method allowed controlled attachment of the drug to the antibody, which is critical for consistent drug-to-antibody ratios.
Key Numbers
Dose-dependent cytotoxicity in vitro; higher anti-tumor activity than antibody alone in vivo; CCAP peptide linker conjugation
How They Did This
This was a preclinical study. Researchers created the ADC using the CCAP method to conjugate emtansine to the P38B antibody via a peptide linker. Cytotoxicity was tested in vitro against CHO cells overexpressing dog podoplanin. Anti-tumor activity was tested in a mouse xenograft model.
Why This Research Matters
Antibody-drug conjugates are one of the fastest-growing areas in cancer therapy. Using peptide linkers offers advantages in controlling how and when the drug is released from the antibody.
While this specific ADC targets canine cancers (melanoma and squamous cell carcinoma), the CCAP conjugation method and peptide linker technology could be applied to human cancer targets.
The Bigger Picture
ADCs are one of the fastest-growing cancer drug classes. Peptide linker technology offers advantages in controlling where and how the drug is released from the antibody, potentially improving both efficacy and safety. This veterinary-focused study validates the CCAP conjugation approach.
What This Study Doesn't Tell Us
The xenograft model used artificially overexpressing cells rather than naturally occurring tumors. Results in natural canine cancers may differ.
The study focused on a veterinary target (dog podoplanin) and would need separate development for human applications. Safety data was not reported.
Questions This Raises
- ?Can the CCAP method be applied to human-targeting ADCs?
- ?How does CCAP linker stability compare to conventional linker chemistries?
- ?Would this ADC work against natural canine tumors in veterinary oncology?
Trust & Context
- Key Stat:
- CCAP peptide linker enabled a functional ADC with superior anti-tumor activity compared to antibody alone, validating this conjugation technology
- Evidence Grade:
- Preliminary evidence from a xenograft model using artificially overexpressing cells. Natural tumor activity not tested.
- Study Age:
- Published in 2020. ADC technology continues to advance with multiple new approvals annually.
- Original Title:
- Antibody-Drug Conjugates Using Mouse-Canine Chimeric Anti-Dog Podoplanin Antibody Exerts Antitumor Activity in a Mouse Xenograft Model.
- Published In:
- Monoclonal antibodies in immunodiagnosis and immunotherapy, 39(2), 37-44 (2020)
- Authors:
- Kato, Yukinari, Ito, Yuji(2), Ohishi, Tomokazu, Kawada, Manabu, Nakamura, Takuro, Sayama, Yusuke, Sano, Masato, Asano, Teizo, Yanaka, Miyuki, Okamoto, Saki, Handa, Saori, Komatsu, Yu, Takei, Junko, Kaneko, Mika K
- Database ID:
- RPEP-04901
Evidence Hierarchy
Frequently Asked Questions
What is CCAP technology?
Chemical Conjugation by Affinity Peptide (CCAP) uses a specific peptide sequence to control where drugs attach to antibodies. This precise control over conjugation site can improve the consistency and effectiveness of antibody-drug conjugates.
Why develop this for dog cancer?
Companion animal cancer is a significant veterinary market, and canine cancers can serve as natural disease models for human cancer. The CCAP technology demonstrated here could also be applied to human ADC development.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04901APA
Kato, Yukinari; Ito, Yuji; Ohishi, Tomokazu; Kawada, Manabu; Nakamura, Takuro; Sayama, Yusuke; Sano, Masato; Asano, Teizo; Yanaka, Miyuki; Okamoto, Saki; Handa, Saori; Komatsu, Yu; Takei, Junko; Kaneko, Mika K. (2020). Antibody-Drug Conjugates Using Mouse-Canine Chimeric Anti-Dog Podoplanin Antibody Exerts Antitumor Activity in a Mouse Xenograft Model.. Monoclonal antibodies in immunodiagnosis and immunotherapy, 39(2), 37-44. https://doi.org/10.1089/mab.2020.0001
MLA
Kato, Yukinari, et al. "Antibody-Drug Conjugates Using Mouse-Canine Chimeric Anti-Dog Podoplanin Antibody Exerts Antitumor Activity in a Mouse Xenograft Model.." Monoclonal antibodies in immunodiagnosis and immunotherapy, 2020. https://doi.org/10.1089/mab.2020.0001
RethinkPeptides
RethinkPeptides Research Database. "Antibody-Drug Conjugates Using Mouse-Canine Chimeric Anti-Do..." RPEP-04901. Retrieved from https://rethinkpeptides.com/research/kato-2020-antibodydrug-conjugates-using-mousecanine
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.